Haixi Pharma (02637) announced interim results
- RevenueRMB3.1bn
- Net profitRMB81.0M
- Profit attributable to ownersRMB81.0M
- Revenue YoY+3.8%
- Net profit YoY-24.8%
- Depreciation & amortisationHK$7.7M
- Capital expenditureHK$-44.9M
- Interest-bearing debtHK$83.3M
Source Haixi Pharma



